• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Spartan Capital Securities Serves as Sole Placement Agent in Virpax Pharmaceuticals' $6 Million Follow-On Offering

    1/30/25 3:59:11 PM ET
    $VRPX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VRPX alert in real time by email

    NEW YORK, NY, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a leading full-service investment banking and financial advisory firm, is proud to announce its role as sole placement agent for Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) in the successful close of its $6 million follow-on offering.

    Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) is a preclinical-stage pharmaceutical company pioneering novel drug delivery systems for pain management and central nervous system disorders. The proceeds from the offering will enable Virpax to support the ongoing clinical trial development of Probudur, fund marketing and advertising efforts, for general corporate purposes, and to provide working capital.

    "We are pleased to support Virpax Pharmaceuticals in this offering and look forward to seeing the continued progress of their innovative drug delivery technologies," said John Lowry, CEO of Spartan Capital Securities. "Spartan Capital remains committed to helping emerging biotech and pharmaceutical companies access the capital they need to advance groundbreaking solutions that address unmet medical needs."

    Legal counsel for Virpax Pharmaceuticals was provided by Sichenzia Ross Ference Carmel LLP, with representation by Ross Carmel and Benjamin Sklar. Spartan Capital Securities was represented by Lucosky Brookman LLP, with Scott Linsky, Raymond Ressy, and Xiafan Cheng serving as counsel.

    This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction where such offer, solicitation, or sale would be unlawful prior to registration or qualification under applicable securities laws.

    About Virpax Pharmaceuticals, Inc.

    Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) is a preclinical-stage pharmaceutical company focused on developing novel and proprietary drug delivery systems to address various pain indications and enhance compliance. The company's innovative pipeline aims to advance non-opioid and non-addictive treatments for pain and central nervous system disorders, improving the quality of life for patients worldwide.

    About Spartan Capital Securities, LLC

    Spartan Capital Securities, LLC is a premier full-service investment banking firm offering a comprehensive range of advisory services to institutional clients and high-net-worth individuals. Known for its expertise in capital raising, strategic advisory, and asset management, Spartan Capital delivers tailored solutions to meet clients' financial goals. For more information about Spartan Capital Securities, visit www.spartancapital.com.

    Contact:

    Spartan Capital Securities, LLC

    45 Broadway, 19th Floor

    New York, NY 10006

    [email protected]



    Primary Logo

    Get the next $VRPX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VRPX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VRPX
    SEC Filings

    View All

    SEC Form 25-NSE filed by Virpax Pharmaceuticals Inc.

    25-NSE - Virpax Pharmaceuticals, Inc. (0001708331) (Subject)

    7/21/25 2:57:48 PM ET
    $VRPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Virpax Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update, Financial Statements and Exhibits

    8-K/A - Virpax Pharmaceuticals, Inc. (0001708331) (Filer)

    4/3/25 5:00:46 PM ET
    $VRPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Virpax Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update, Financial Statements and Exhibits

    8-K - Virpax Pharmaceuticals, Inc. (0001708331) (Filer)

    4/3/25 11:00:41 AM ET
    $VRPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VRPX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Panis Jaydriane

    3 - Virpax Pharmaceuticals, Inc. (0001708331) (Issuer)

    1/8/25 4:11:17 PM ET
    $VRPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Chaudhry Usama

    3 - Virpax Pharmaceuticals, Inc. (0001708331) (Issuer)

    1/6/25 4:05:29 PM ET
    $VRPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Randhawa Esha

    3 - Virpax Pharmaceuticals, Inc. (0001708331) (Issuer)

    12/4/24 8:30:14 PM ET
    $VRPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VRPX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Virpax Pharmaceuticals Announces Reverse Stock Split

    Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) ("Virpax" or the "Company") a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced that it will effect a 1-for-25 reverse stock split ("reverse split") of its common stock, par value $0.0001 per share ("Common Stock"), that will become effective at 12:01 a.m. Eastern Time on March 20, 2025. The Company's Common Stock will continue to trade on the Nasdaq Capital Market ("Nasdaq") under the symbol "VRPX" and will begin trading on a split-adjusted basis when the Nasdaq opens on March 21, 2025 ("Effective

    3/19/25 8:00:00 AM ET
    $VRPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Virpax Receives Positive Probudur™ Results for Dose Range Study Moves Towards Next Steps in IND

    Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) ("Virpax" or the "Company"), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced positive results from a beagle dog dose range finding ("DRF") study. Probudur is the company's long-acting liposomal bupivacaine formulation injected at a wound site to provide both immediate and extended pain relief. The Company continues to work towards its Investigational New Drug (IND) application and this was another important step towards that milestone. The DRF study was conducted to evaluate the tolerance of Pr

    3/18/25 4:01:00 PM ET
    $VRPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Virpax Looking to Use MET to Develop Intranasal COVID Vaccine

    Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) ("Virpax" or the "Company"), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, is looking to use Molecular Envelope Technology (MET) or a similar technology to deliver a mRNA COVID vaccine. Virpax currently uses its MET for Envelta (NES100) and NobrXiol (VRP324). The Company will look to explore delivery of vaccines via intranasal delivery similar to the FluMist which is used for patients with a fear of needles. The current vaccines in the market use lipid delivery technology to deliver mRNA to induce an immune

    3/7/25 8:00:00 AM ET
    $VRPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VRPX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Virpax Pharmaceuticals Inc.

    SC 13G - Virpax Pharmaceuticals, Inc. (0001708331) (Subject)

    5/23/24 4:06:37 PM ET
    $VRPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Virpax Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Virpax Pharmaceuticals, Inc. (0001708331) (Subject)

    1/2/24 10:11:28 AM ET
    $VRPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Virpax Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Virpax Pharmaceuticals, Inc. (0001708331) (Subject)

    2/14/23 4:05:43 PM ET
    $VRPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VRPX
    Leadership Updates

    Live Leadership Updates

    View All

    Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer

    GLEN ALLEN, Va., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the appointment of Vinay Shah as the Company's Chief Financial Officer, effective November 16, 2024. Vinay Shah is an accomplished Chief Financial Officer with over 25 years of experience in the pharmaceutical, biopharmaceutical, and healthcare sectors, specializing in financial strategy, investor relations, and operational efficiency. Most recently, Mr. Shah served as the CFO at Virpax Pharmaceuticals, Inc. (N

    11/5/24 8:30:00 AM ET
    $ADIL
    $VRPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Virpax Pharmaceuticals Announces Leadership Transition

    Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced that due to ongoing litigation it has accepted the resignation of Anthony P. Mack as CEO and Chairman effective immediately. The Board has appointed Gerald Bruce as CEO and Dr. Eric Floyd as Chairman. Mr. Bruce has served as the Company's Executive Vice President of Commercial Operations since August 2017, as a member of the Company's Board since July 2021 and as the President and CEO of the Company's wholly owned su

    11/17/23 7:00:00 AM ET
    $VRPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Virpax Pharmaceuticals Announces Appointment of Barbara A. Ruskin, Ph.D, J.D. to the Board of Directors

    Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, announced today that the Company has appointed Barbara A. Ruskin, Ph.D, J.D. to its Board of Directors, increasing the size of the Board to nine members. Dr. Ruskin, who received her Ph.D. in Biochemistry & Molecular Biology from Harvard University, is an experienced attorney specializing in life sciences and intellectual property. Most recently she serves as the Chief Intellectual Property and Innovation Officer for Silence Therapeutics,

    3/28/23 8:58:00 AM ET
    $VRPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VRPX
    Financials

    Live finance-specific insights

    View All

    Virpax Pharmaceuticals Reports 2024 First Quarter Results and Recent Developments

    Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its financial results for the three months ended March 31, 2024, and other recent developments. "We recently reported results for a Probudur™ Maximum Tolerated Dose Study, as we continue to make steady progress in anticipation of filing our IND. The results of this study, as expected, confirmed our belief that a single injection of Probudur was well-tolerated. Our studies to date continue to reaffirm our belief that Probu

    5/13/24 4:10:00 PM ET
    $VRPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Virpax Pharmaceuticals Reports 2023 Year-End Results

    Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its financial results for the twelve months ended December 31, 2023, and other recent developments. "We are off to a strong start in 2024 and are pleased to have regained compliance with Nasdaq. Additionally, we have executed a settlement agreement with the Plaintiffs, and can now focus on developing our non-addictive product candidates for pain management," commented Gerald W. Bruce, Chief Executive Officer of Virpax.

    3/26/24 7:30:00 AM ET
    $VRPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Virpax Pharmaceuticals Reports 2023 Third Quarter Results and Recent Developments

    Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its financial results for the three months ended September 30, 2023, and other recent developments. "We recently announced results from two preclinical studies for Probudur™, our lead product candidate for post operative pain, that demonstrated significantly longer efficacy in animal models than the product currently on the market today. With these solid results, we believe we are on track to file our Investigational New

    11/15/23 4:15:00 PM ET
    $VRPX
    Biotechnology: Pharmaceutical Preparations
    Health Care